Drug Delivery Solutions

Catalent is a leading global provider of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company specializes in optimizing the formulation and delivery of various therapeutic modalities, ranging from traditional small molecules to advanced biologics and personalized medicines. Catalent's proprietary technologies, such as the Zydis fast-dissolve platform and GPEx cell line development, support the entire product lifecycle from early-stage development to commercial supply. With a vast network of facilities worldwide, the company serves as a critical partner for pharmaceutical and biotechnology firms seeking to accelerate their programs to market. In 2024, Catalent entered into a definitive agreement to be acquired by Novo Holdings, the parent company of Novo Nordisk.